Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Intellia Therapeutics (NTLA) Cash from Investing Activities (2016 - 2025)

Historic Cash from Investing Activities for Intellia Therapeutics (NTLA) over the last 11 years, with Q3 2025 value amounting to -$741000.0.

  • Intellia Therapeutics' Cash from Investing Activities rose 9038.79% to -$741000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $352.1 million, marking a year-over-year increase of 166551.83%. This contributed to the annual value of $125.6 million for FY2024, which is 50057.1% up from last year.
  • As of Q3 2025, Intellia Therapeutics' Cash from Investing Activities stood at -$741000.0, which was up 9038.79% from $106.9 million recorded in Q2 2025.
  • Intellia Therapeutics' 5-year Cash from Investing Activities high stood at $151.6 million for Q4 2024, and its period low was -$399.4 million during Q3 2021.
  • For the 5-year period, Intellia Therapeutics' Cash from Investing Activities averaged around -$5.0 million, with its median value being $5.9 million (2024).
  • Its Cash from Investing Activities has fluctuated over the past 5 years, first plummeted by 35751.06% in 2023, then skyrocketed by 149850.87% in 2025.
  • Intellia Therapeutics' Cash from Investing Activities (Quarter) stood at -$159.1 million in 2021, then surged by 81.05% to -$30.2 million in 2022, then soared by 252.36% to $45.9 million in 2023, then surged by 229.93% to $151.6 million in 2024, then plummeted by 100.49% to -$741000.0 in 2025.
  • Its Cash from Investing Activities was -$741000.0 in Q3 2025, compared to $106.9 million in Q2 2025 and $94.3 million in Q1 2025.